Ocata Therapeutics Inc fka OCAT

[NYPharmer1]

Part 4

Investment Highlights

http://www.advancedcell.com/fact-sheet/

Currently ACT is finalizing preclinical studies for the bio-distribution of our therapeutic program addressing Retinal Degeneration (i.e. AMD or macular degeneration in the eye) and has completed GLP Safety Studies and long-term efficacy studies for the RPE therapy with positive results.
The Company expects spiking studies for the RPE product to be finished in the second half of 2009. ACT expects to file the RPE program IND by the end of 2009.
Working on acquiring funding for Phase II clinical trials for the Company’s Myoblast program, an autologous (meaning “one’s own”) adult stem cell therapy for treating cardiac disease. Historically the Myoblast program successfully completed several Phase I clinical trials.
Published positive results from HG program demonstrating hemangioblasts’ ability to repair vascular damage in animals. Therapy could be effective for treatment of blood and cardiovascular diseases. Anticipates filing an IND in 2010.
Made progress in macular degeneration indication by reporting positive data for RPE cell animal study. Entered into collaboration with Casey Eye Institute for preclinical trials. Completed Pre-IND meeting with FDA. Expects to file IND in 2009.
Developed and demonstrated technique to generate embryonic stems that maintain developmental potential of the embryo and therefore has potential to shift the ethical debate. Announced hESC lines created without destroying an embryo in multiple studies.
Owns or licenses over 380 patents and patent applications related to stem cell therapy.
Large Target Market: Regenerative Medicine has potential to treat diseases of the eye, blood disorders, heart disease, neurodegenerative diseases, liver disease, diabetes, and others.
Led by experienced management team and scientific experts including CEO William Caldwell, Chief Scientific Officer Robert Lanza M.D., VP of Regulatory Ed Mickunas, Senior Director of Manufacturing Roger Gay PhD and Director of Operations Rita Parker.